FGFR1 and central nervous system cancer: Screening for FGFR3-TACC3 fusions and FGFR1 activating mutations should be performed in all patients with newly diagnosed IDH wild-type gliomas and all midline gliomas, respectively, as these patients are potentially eligible for clinical trials of targeted therapies at recurrence (Table 2).